Clinical Trial Update: A MultiCenter Study of Combined PEX, Rituximab, and Steroids in Acute Idiopathic Pulmonary Fibrosis Exacerbations [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating plasmapheresis, rituximab, and steroids for acute idiopathic pulmonary fibrosis exacerbations has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• METHYLPREDNISOLONE (methylprednisolone)
• PREDNISONE (Prednisone)
• Rituximab (rituximab)

Snippet

Sponsor: University of Pittsburgh | Conditions: Idiopathic Pulmonary Fibrosis | Phase 2 | Status: WITHDRAWN